Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...

The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average<a class="excerpt-read-more" href=" More ...